ATE294854T1 - Gewebespezifische und ziel-rna-spezifische ribozyme - Google Patents

Gewebespezifische und ziel-rna-spezifische ribozyme

Info

Publication number
ATE294854T1
ATE294854T1 AT96940377T AT96940377T ATE294854T1 AT E294854 T1 ATE294854 T1 AT E294854T1 AT 96940377 T AT96940377 T AT 96940377T AT 96940377 T AT96940377 T AT 96940377T AT E294854 T1 ATE294854 T1 AT E294854T1
Authority
AT
Austria
Prior art keywords
ribozymes
specific
target rna
tissue
nucleic acids
Prior art date
Application number
AT96940377T
Other languages
English (en)
Inventor
James S Norris
Gary A Clawson
Original Assignee
Univ South Carolina
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Carolina, Penn State Res Found filed Critical Univ South Carolina
Application granted granted Critical
Publication of ATE294854T1 publication Critical patent/ATE294854T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07006—DNA-directed RNA polymerase (2.7.7.6)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96940377T 1995-11-08 1996-11-08 Gewebespezifische und ziel-rna-spezifische ribozyme ATE294854T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/554,369 US5824519A (en) 1995-11-08 1995-11-08 Tissue-specific and target RNA-specific ribozymes
PCT/US1996/018088 WO1997017433A1 (en) 1995-11-08 1996-11-08 Tissue-specific and target rna-specific ribozymes

Publications (1)

Publication Number Publication Date
ATE294854T1 true ATE294854T1 (de) 2005-05-15

Family

ID=24213065

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96940377T ATE294854T1 (de) 1995-11-08 1996-11-08 Gewebespezifische und ziel-rna-spezifische ribozyme

Country Status (9)

Country Link
US (1) US5824519A (de)
EP (2) EP0866852B1 (de)
JP (2) JP4033902B2 (de)
CN (1) CN1207769A (de)
AT (1) ATE294854T1 (de)
AU (1) AU728732B2 (de)
DE (1) DE69634698T2 (de)
IL (1) IL124383A0 (de)
WO (1) WO1997017433A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024925A1 (en) * 1995-11-08 1998-06-11 Medical University Of South Carolina Tissue specific and target rna-specific ribozymes as antimicrobial therapeutics against microbial pathogens
US20030125280A1 (en) * 1996-12-03 2003-07-03 Medical University Of South Carolina Tissue specific and target RNA-specific ribozymes as antimicrobial therapeutics against microbial pathogens
JP4312957B2 (ja) 1998-01-15 2009-08-12 キングス・カレツジ・ロンドン Ｃｃｒ５あるいはｃｘｃｒ４を開裂するリボザイム核酸
WO1999067400A1 (en) * 1998-06-24 1999-12-29 Musc Foundation For Research Development Tissue-specific and target rna-specific ribozymes
AU2004201285B2 (en) * 1998-06-24 2007-07-05 Musc Foundation For Research Development Tissue-specific and target RNA-specific ribozymes
US6242589B1 (en) * 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
EP1147413B1 (de) * 1999-01-21 2006-04-05 Metamorphix, Inc. Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP2002541822A (ja) * 1999-04-14 2002-12-10 エム ユー エス シー ファンデーション フォー リサーチ ディベロップメント 組織特異的および病原体特異的毒性物質ならびにリボザイム
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP1702983A3 (de) 2000-04-13 2007-01-10 Medical University of South Carolina Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisenseolinukleotide sowie Anwendungen dafür
WO2002046449A2 (en) * 2000-12-07 2002-06-13 The Penn State Research Foundation Selection of catalytic nucleic acids targeted to infectious agents
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2004002416A2 (en) * 2002-06-26 2004-01-08 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
EP1611231A4 (de) * 2003-02-21 2008-08-13 Penn State Res Found Rna-interferenz-zusammensetzungen und -verfahren
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
EP1648935A2 (de) 2003-07-25 2006-04-26 Amgen Inc. Antagonisten und agonisten von ldcam und anwendungsverfahren
GB0522578D0 (en) * 2005-11-04 2005-12-14 King S College London Ribozymal nucleic acid
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
EP2307456B1 (de) 2008-06-27 2014-10-15 Amgen Inc. Die inhibierung von ang-2 zur behandlung multipler sklerose
CA2793521A1 (en) 2010-03-19 2011-09-22 University Of South Alabama Use of antisense gli1 for reducing the dosage of a therapeutic compound to treat needed to treat a cancer
US9458456B2 (en) 2011-04-01 2016-10-04 University Of South Alabama Methods and compositions for the diagnosis, classification, and treatment of cancer
WO2013103401A1 (en) 2012-01-06 2013-07-11 University Of South Alabama Methods and compositions for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115999T1 (de) * 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
DE3933384A1 (de) * 1989-10-06 1991-04-18 Hoechst Ag Multifunktionelle rna mit selbstprozessierungsaktivitaet, ihre herstellung und ihre verwendung
JP2507895B2 (ja) * 1989-12-19 1996-06-19 工業技術院長 リボザイムの新規合成系
US5500357A (en) * 1990-11-02 1996-03-19 Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry RNA transcription system using novel ribozyme
JP2580512B2 (ja) * 1990-11-02 1997-02-12 工業技術院長 リボザイムを用いた新規ｒｎａ転写システム
WO1992010590A1 (en) * 1990-12-10 1992-06-25 Gilead Sciences, Inc. Inhibition of transcription by formation of triple helixes
GB9216851D0 (en) * 1992-08-07 1992-09-23 Univ Manitoba Dna sequences of rat probasin gene

Also Published As

Publication number Publication date
JP4033902B2 (ja) 2008-01-16
DE69634698D1 (de) 2005-06-09
DE69634698T2 (de) 2006-01-19
IL124383A0 (en) 1998-12-06
US5824519A (en) 1998-10-20
AU728732B2 (en) 2001-01-18
EP1561815A2 (de) 2005-08-10
JP2007084550A (ja) 2007-04-05
AU7727296A (en) 1997-05-29
EP0866852A1 (de) 1998-09-30
CN1207769A (zh) 1999-02-10
EP1561815A3 (de) 2007-11-07
WO1997017433A1 (en) 1997-05-15
JP2000500967A (ja) 2000-02-02
EP0866852B1 (de) 2005-05-04

Similar Documents

Publication Publication Date Title
ATE294854T1 (de) Gewebespezifische und ziel-rna-spezifische ribozyme
EP1250455A4 (de) Antisense inhibierung der ptp1b expression.
EP1248791A4 (de) Antisens-modulierung der caspase 3 expression
EP1325019A4 (de) Antisense-modulation der clusterinexpression
EP1417351A4 (de) Antisense-modulation der expression von apolipoprotein(a)
EP1131465A4 (de) Antisense-modulierung der interleukin-15 expression
EP1250157A4 (de) Antisens-modulation der expression der induzierbaren stickstoffmonoxid-synthase
EP1248794A4 (de) Antisens-modulierung der smad7 expression
EP1419168A4 (de) Antisense-modulation der expression von apolipoprotein b
DK1117672T3 (da) Antisense-modulation af survivin-ekpression
EP1409509A4 (de) Antisense-modulation der expression von c-reactive-protein
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
EP1189918A4 (de) Antisense-modulation der integrin-beta-3-expression
EP1135402A4 (de) Antisense modulation der egr-1 expression
DE69839489D1 (de) Impfstoff zur vorbeugung bzw. behandlung der hepatitis c
EP1131107A4 (de) Antisense-modulation der expression von inhibitor-kappa-b-kinase-alpha
WO2001029175A3 (en) Antisense modulation of fra-1 expression
EP1268507A4 (de) Antisense-modulation der expression des transkriptionsfaktors e2f-1
EP1144690A4 (de) Antisense modulation der expression des zellulären hemmstoffs der apoptose-2
EP1165145A4 (de) Antisense-modulation der mdmx-expression
EP1163373A4 (de) Antisense-modulation des zellulären hemmstoffs der apoptosis-expression
CA2236998A1 (en) Tissue-specific and target rna-specific ribozymes
EP1235924A4 (de) Antisense modulation der rank expression
DE69433996D1 (de) Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten
DK0625194T3 (da) Forøgelse af ribozym-katalytisk aktivitet med et tilstødende facilitator oligonukleotid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties